Clinical trials: Disorder, Mood
Depressive Disorder, Treatment-Resistant
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms…
- Trial name
- SUSTAIN-1 (NCT02493868)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 155 sites in United States, Belgium and 13 more
- Volunteers
- 719 people
- Sponsor
- Janssen Research & Development, LLC
Treatment Resistant Depression
Pharmacogenomics for Antidepressant Guidance and Education
More than one out of three individuals treated for major depressive disorder (MDD) do not experience a full reduction of symptoms even when treated with adequate antidepressant medication.
- Trial name
- NCT01555021
- Testing
- Genotyping assays
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Massachusetts General Hospital
Depression, Mood Disorders
Rapid Antidepressant Effects of Ketamine in Major Depression
Depressive disorders may be severe, chronic and often life-threatening illnesses. Impairment in physical and social functioning resulting from depression can be just as severe as other chronic medical illnesses.
- Conditions
- Depression, Mood Disorders, Major Depresssion
- Trial name
- NCT00088699
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Epilepsy, Schizophrenia
Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME)
For this project we propose to refine the psychosocial intervention developed in phase one, based on input from key stakeholders, and to test the feasibility, acceptability and preliminary efficacy of the intervention.
- Conditions
- Epilepsy, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01992393
- Testing
- TIME
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Western Reserve University
Major Depression, End Stage Renal Disease
Bupropion for Depression in ESRD Patients on Hemodialysis
The proposed study will evaluate the response and remission rates for major depressive disorder (MDD) in end-stage renal disease (ESRD) patients undergoing maintenance hemodialysis (HD) treated with bupropion or fluoxetine for 12…
- Trial name
- NCT02238977
- Testing
- Fluoxetine, Bupropion
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Arkansas
Major Depressive Disorder (MDD)
Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression
This feasibility study investigates effects of EEG-based low frequency, low emission magnetic cortical stimulation in comparison to a sham treatment in subjects with moderate to severe depressive disorder.
- Trial name
- NCT01683019
- Testing
- NeoSync EEG Synchronization Therapy
- Where
- 2 sites in United States, China
- Volunteers
- 52 people
- Sponsor
- Wave Neuroscience
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
This a Phase 2a, multicenter, randomized, double-blind, placebo controlled 3 arm study to assess the safety and tolerability of multiple oral doses of REL-1017 25 mg and 50 mg as adjunctive therapy in the treatment of patients…
- Trial name
- NCT03051256
- Testing
- REL-1017
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Relmada Therapeutics, Inc.
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Major Depressive Disorder
The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder.
- Trial name
- VLZ-MD-01 (NCT01473381)
- Testing
- Vilazodone, Citalopram
- Where
- 54 sites in United States
- Volunteers
- 1,162 people
- Sponsor
- Forest Laboratories
Bipolar Disorder
Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)
The purpose of this study is to assess the safety and tolerability of ziprasidone during long-term open-label administration in children and adolescents (ages 10-17) with bipolar I disorder (manic or mixed)
- Trial name
- NCT00265330
- Testing
- Ziprasidone oral capsules
- Where
- 41 sites in United States
- Volunteers
- 169 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depressive Disorder
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
To evaluate the long-term efficacy and safety of brexpiprazole as an adjunctive treatment to an antidepressant treatment (ADT) for adult patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01838681
- Testing
- Brexpiprazole, ADT
- Where
- 107 sites in United States, Bulgaria and 14 more
- Volunteers
- 1,986 people
- Sponsor
- H. Lundbeck A/S
Premenstrual Dysphoric Disorder
Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)
The purpose of this study is to compare a low dose oral contraceptive (OC) given continuously (every day for three months) with the same low dose oral contraceptive given in an interrupted regimen (one week of inactive placebo…
- Trial name
- PMDD (NCT00927095)
- Testing
- Continuous OC (EE/DROS), Intermittent OC (EE/DROS)
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of North Carolina, Chapel Hill
Depression
Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression
This study will use measurements of depression symptoms and brain activity to determine what factors may influence an individual's response to treatment for depression.
- Trial name
- NCT00200902
- Testing
- Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro), Interpersonal Clinical Interaction (ICI)
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder
Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)
The objective of this study is to allow patients who have participated in the precursor study of BCI-024 in combination with BCI-049 versus placebo or BCI-024 alone (Protocol #CBM-IT-01) to receive 6 weeks of open-label treatment…
- Trial name
- NCT00731653
- Testing
- Combination Product: BCI-024 + BCI-049
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder
This is a study with an Open-Label (OL) phase followed by a randomized, Double-Blind (DB), placebo-controlled phase to assess efficacy and safety of SAGE-217 on relapse prevention in adults with major depressive disorder (MDD).
- Trial name
- NCT04007367
- Testing
- SAGE-217
- Where
- 46 sites in United States
- Volunteers
- 53 people
- Sponsor
- Biogen
Schizophrenia, Psychotic Disorders
A Brief Community Linkage Intervention for Dually Diagnosed Individuals
Surveys suggest that up to 80% of veterans with a persistent mental illness have a co-occurring substance use disorder. Substance abuse among this population is problematic and often results in poor engagement in treatment and…
- Conditions
- Schizophrenia, Psychotic Disorders, Substance-Related Disorders, Bipolar Disorder
- Trial name
- TLC (NCT00137267)
- Testing
- Time limited case management, Health Education
- Where
- 2 sites in United States
- Volunteers
- 102 people
- Sponsor
- US Department of Veterans Affairs
Major Depressive Disorder
Pilot Study of Open-label Placebo to Treat Major Depressive Disorder
Placebo pills (pills with no active ingredients) have been shown in research studies to somehow produce self-healing processes. The purpose of this study is to determine whether people will be willing to enter an open-label…
- Trial name
- NCT01103271
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Major Depression
Behavior During Experimentally Induced Pain
Numerous factors can influence the processing of pain message: the affective or emotional, the sensorial and the cognitive components.
- Trial name
- NCT01594528
- Testing
- pain tests
- Where
- France
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Esquirol
Generalized Anxiety Disorder
An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in treating Generalized Anxiety Disorder.
- Trial name
- NCT00734071
- Testing
- Vortioxetine
- Where
- 33 sites in United States
- Volunteers
- 304 people
- Sponsor
- Takeda
Major Depressive Disorder
A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy in patients with major depressive disorder.
- Trial name
- NCT02395978
- Testing
- PDC-1421 Capsule
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 72 people
- Sponsor
- BioLite, Inc.
Medication Adherence, Bipolar Disorder
Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad)
Psychotropic-related weight gain is a common concern among patients with bipolar disorder (BD). This concern affects an individual's satisfaction with treatment and may lead to reduced adherence and illness relapse.
- Trial name
- Zip Ad (NCT01293825)
- Testing
- ziprasidone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University Hospitals Cleveland Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.